Apixaban for VTE prophylaxis after THA

In this large industry sponsored randomized trial of apixaban (an oral Xa inhibitor) versus enoxaparin in patients post-hip THA, patients were treated for 35 days, and followed up at an additional 60 days for the primary outcome (DVT/PE/Death). Patients in the apixaban group had significantly fewer events than the enoxaparin group (1% versus 4%). Apixaban, similar to rivaroxaban, are both oral Xa inhibitors that are effective in preventing VTE after orthopedic surgeries. However, neither are yet FDA approved in the US, and cost remains to be seen (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment